StockKit ResearchEQUITY RESEARCH BRIEF
GILD · US · Fresh
Generated 2026-09-12 14:23 UTC
GILD
GILD · US
$130.52
+0.94%
Technical posture
Constructive
Strategy score
65 / 100
Trend
bull
Data confidence
High
Research view
GILD Research Preview
1. Bottom line
- GILD (GILD) is trading at 130.52, with a current daily move of +0.94%.
- The StockKit strategy score is 65/100, creating a neutral research posture with bullish alignment (ma5 > ma10 > ma20 > ma60).
- The most important near-term watch zone is support at 127.60 and resistance at 138.05; price is +2.24% from support and +5.77% from resistance.
2. Key data snapshot
| Item | Reading | Interpretation |
|---|---:|---|
| Current price | 130.52 | Daily move +0.94% |
| Strategy score | 65/100 | Buy, trend: bull |
| MA structure | Bullish alignment (MA5 > MA10 > MA20 > MA60) | The short-term moving average is above the medium-term moving average, which points to a firmer near-term structure. |
| RSI14 | 62.06 | Constructive but not extreme |
| MACD | 0.60 histogram | Bullish MACD configuration |
| Support / resistance | 127.60 / 138.05 | Watch these levels for confirmation or failure |
| 30-session range | 127.61 / 140.61 | Price sits at +22.38% of the range |
| Volume check | -49.42% vs 20D avg | Confirmation quality depends on volume follow-through |
| ATR14 / price | +2.93% | Proxy for short-term volatility risk |
3. Technical indicator panel
- Trend: The short-term moving average is above the medium-term moving average, which points to a firmer near-term structure.
- Momentum: RSI14 is not giving an extreme signal, so confirmation from price structure matters more than momentum alone.
- MACD: histogram is 0.60, while MACD line / signal are 1.61 / 1.01.
- KDJ: K / D / J are 83.54 / 68.67 / 113.26; KDJ extended / short-term overheating risk.
- Bollinger: Mid-band zone (28% of band); upper / middle / lower are 138.05 / 132.82 / 127.60.
- ATR / OBV / CCI: ATR14 is 4.05 (+2.93% of price), OBV slope is +2.22%, and CCI20 is 167.12.
- Levels: estimated support / resistance are 127.60 / 138.05; recent 30-session range is 127.61 / 140.61.
4. Valuation matrix
| Axis | Reading | Source | Confidence |
|---|---|---|---|
| PE | 19.25 | SEC EDGAR companyfacts | Medium |
| PB | 13.85 | SEC EDGAR companyfacts | Medium |
| Price / sales | 5.56 | SEC EDGAR companyfacts | Medium |
| EV/EBITDA | 18.42 | SEC EDGAR companyfacts | Low |
| PEG proxy | 1.07 | StockKit scenario model | Medium |
| StockKit fair value range | Bear $135.95 / Base $186.96 / Bull $234.91 | StockKit DCF scenario model | Medium |
| Base fair-value gap | +43.2% | StockKit DCF scenario model | Medium |
| 5Y growth forecast | Bear +10.00% / Base +18.00% / Bull +24.00% | StockKit scenario model | Medium |
| Revenue | $29.44B | SEC EDGAR companyfacts | High |
| Net income | $8.51B | SEC EDGAR companyfacts | High |
| Market cap | $163.80B | SEC shares outstanding + live quote | Medium |
| Balance sheet context | Assets $49.36B / Equity $11.83B | SEC EDGAR companyfacts | High |
Notes: - SEC CIK: 0000882095; company: GILEAD SCIENCES, INC.. - Latest annual income-statement period used where available: 2025-12-31. - PEG and fair-value range are StockKit scenario outputs computed from reported fundamentals; they are not analyst consensus targets.
5. News and catalyst timeline
1. Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? - Biztoc.com
2. Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them? - 24/7 Wall St.
3. Robert Pattinson o męczących zdjęciach do nowego "Batmana": czuję swój wiek - Interia.pl
4. Is Gilead Sciences Stock Outperforming the S&P 500? - Barchart.com
6. Sentiment radar
5 recent headlines available; no provider-level sentiment score was supplied.
| Source | Status | Reading | Confidence |
|---|---|---|---|
| NewsAPI headline coverage | 5 headlines | Biztoc.com x1, 24/7 Wall St. x1, Interia.pl x1 | Medium |
| Social sentiment | Not connected | No social sentiment conclusion is drawn | Low |
Notes: - No provider sentiment series was returned for this symbol.
7. Scenario framework
| Scenario | Trigger condition | Confirmation signal | Invalidation signal |
|---|---|---|---|
| Base case | Price remains between 127.60 and 138.05 | Strategy score stays near 65/100 and RSI avoids extremes | Close below support or a rapid score deterioration |
| Upside case | Price clears 138.05 | Improving MACD histogram and volume above 20D average | Failed breakout back below resistance |
| Downside case | Price breaks 127.60 | RSI weakens and MACD remains negative | Quick recovery back above support |
8. Risk matrix
| Risk | Evidence | Trigger | Monitoring action |
|---|---|---|---|
| Technical failure | Support at 127.60 anchors the current setup | Close below support | Reassess trend and reduce confidence in base case |
| Momentum exhaustion | Constructive but not extreme; MACD state: Bullish MACD configuration | RSI extension or MACD rollover | Watch next 1-3 closes and histogram direction |
| Volatility expansion | ATR14 / price is +2.93% | Wide ranges without follow-through | Require confirmation before trusting a directional move |
| News/data gap | 5 current news items available | New headline or missing catalyst context | Refresh news before relying on stale views |
9. Seven-day watch checklist
- First watch: whether price respects 127.60 or starts accepting below it.
- Breakout watch: whether price can clear 138.05 with volume confirmation above the 20-session average.
- Momentum watch: whether RSI14 stays constructive without moving into an exhaustion zone.
- Risk watch: whether fresh news changes the catalyst picture.
Strategy cross-check
| Strategy | Score | Signal | Basis |
|---|---|---|---|
| MA交叉 | 90/100 | StrongBuy | MA5>MA20金叉，多头排列 |
| MACD背离 | 85/100 | StrongBuy | MACD金叉，MACD在零轴上方，动能增强 |
| RSI极值 | 45/100 | Hold | RSI14=62偏高 |
| 布林带 | 40/100 | Hold | 突破上轨，短期超买，带宽扩张中 |
Information-use note
StockKit provides market research tools for informational and educational use. The output does not constitute personalized investment advice or a recommendation to buy, sell, or hold any security.
Strategy factors
MA交叉Strong momentum
90
MA5>MA20金叉，多头排列
MACD背离Strong momentum
85
MACD金叉，MACD在零轴上方，动能增强
RSI极值Neutral
45
RSI14=62偏高
布林带Neutral
40
突破上轨，短期超买，带宽扩张中
量价关系Neutral
55
价涨量缩，上涨力度不足
News & catalyst inputs
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Biztoc.com · 2026-09-05
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
24/7 Wall St. · 2026-09-04
Robert Pattinson o męczących zdjęciach do nowego "Batmana": czuję swój wiek
Interia.pl · 2026-09-03
Is Gilead Sciences Stock Outperforming the S&P 500?
Barchart.com · 2026-09-03
Gifts from Our Mortal Enemies
Hoover.org · 2026-09-03
Research boundary
StockKit organizes market data and model output for research workflows. It does not provide personalized advice or trade instructions. Verify important information with primary sources before any investment decision.
Disclaimer.This brief is generated by StockKit AI from public market data and algorithmic models for informational research only. It is not investment advice, an offer, or a solicitation, and it does not provide buy, sell, or hold ratings, price targets, stop-loss levels, or position sizing. “Watch levels” and “scenarios” describe observable conditions in the supplied data, not instructions. Verify all information with primary sources before any investment decision.